{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000879169","name":"INCYTE CORP","summary":"Incyte Corporation is a global biopharmaceutical company focused on discovery, development, and commercialization of proprietary therapeutics in three areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its approved products include JAKAFI (ruxolitinib) for MF, PV, and GVHD; ICLUSIG (ponatinib) for CML and Ph+ ALL; MONJUVI/MINJUVI (tafasitamab) for DLBCL and FL; NIKTIMVO (axatilimab-csfr) for chronic GVHD; PEMAZYRE (pemigatinib) for cholangiocarcinoma; and ZYNYZ (retifanlimab-dlwr). Headquartered in Wilmington, Delaware, with European, Japanese, and Canadian offices.","people":[],"products":[{"name":"JAKAFI (ruxolitinib)","type":"service","description":"FDA-approved JAK inhibitor for myelofibrosis, polycythemia vera, and graft-versus-host disease."},{"name":"ICLUSIG (ponatinib)","type":"service","description":"Kinase inhibitor approved in Europe for CML and Ph+ ALL, targeting BCR-ABL including T315I mutation."},{"name":"MONJUVI/MINJUVI (tafasitamab)","type":"service","description":"Anti-CD19 antibody approved for relapsed/refractory DLBCL and follicular lymphoma in the US, EU, and Japan."},{"name":"NIKTIMVO (axatilimab-csfr)","type":"service","description":"Anti-CSF-1R antibody approved by FDA in August 2024 for chronic GVHD after at least two prior therapy lines."},{"name":"PEMAZYRE (pemigatinib)","type":"service","description":"Selective FGFR inhibitor approved for previously treated cholangiocarcinoma with FGFR2 fusion or rearrangement."},{"name":"ZYNYZ (retifanlimab-dlwr)","type":"service","description":"Approved oncology product in Incyte's oncology franchise."},{"name":"JAKAFI XR (ruxolitinib XR)","type":"service","description":"Once-daily extended-release formulation of ruxolitinib in development; CRL response submitted, decision anticipated mid-2026."},{"name":"INCA033989 (mutCALR)","type":"service","description":"Investigational anti-mutant calreticulin monoclonal antibody in Phase 1 for ET and MF; FDA Breakthrough Therapy designation granted December 2025."},{"name":"INCA035784 (mutCALRxCD3 bispecific)","type":"service","description":"Novel T-cell redirecting mutCALR x CD3 bispecific antibody in evaluation for mutCALR-positive MPNs."},{"name":"INCB160058 (JAK2V617Fi)","type":"service","description":"Novel JAK2V617F mutant-specific inhibitor in Phase 1 for MPN patients harboring JAK2V617F mutation."}],"partnerships":[{"partner_name":"Novartis Pharmaceutical International Ltd.","partnership_type":"licensing","description":"Exclusive development and commercialization rights to ruxolitinib outside the US for hematologic and oncologic indications; sold as JAKAVI.","start_date":null},{"partner_name":"MorphoSys AG","partnership_type":"licensing","description":"Original collaboration and license agreement for tafasitamab; Incyte acquired exclusive global rights via purchase agreement in February 2024.","start_date":null},{"partner_name":"Syndax Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab (NIKTIMVO), entered September 2021.","start_date":null},{"partner_name":"Enable Injections, Inc.","partnership_type":"licensing","description":"Worldwide exclusive license to use enFuse on-body delivery system with INCA033989 in ET and MF, announced October 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"4f651051ad37b929f065c303d5f1aa07e7858cdb1ca5c71cad76f665115fbc55","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2180cfed0492bb24f4851695441e0cbe88c525aa2ad953d2492c062682b94d24","parent":"d14f5f5fab1ba49de03d8f7de82f0d0d10e22630a5b57398f143d3ebda78b5d0","source":"0000879169-26-000010","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":152,"hourly_limit":500,"remaining":348,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}